RxDoctor Payments Data

Elaine McGinty

Nurse Practitioner · Hershey, PANPI 1164823308

Payments from drug & device makers

$1,819in general payments, 2019–2025

Across 22 payments — averaging $82.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$441
  • Tandem Diabetes Care, Inc.$344
  • Abbott$329
  • Lilly USA, LLC$203
  • Novo Nordisk$125
  • BETA Bionics, Inc.$111
  • plus $266 from 4 others

What the payments were for

  • Food & beverage$1,819100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,819 in reported general payments places this provider in the 85th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$16,133
Medicare patients
111
Services billed
213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide355$602,050
JardianceEmpagliflozin183$248,747
TrulicityDulaglutide114$180,817
OzempicSemaglutide101$160,125
Tresiba Flextouch U-200Insulin Degludec109$155,120
Fiasp FlextouchInsulin Aspart (Niacinamide)49$59,514
Novolog FlexpenInsulin Aspart236$54,448
FarxigaDapagliflozin Propanediol57$54,086
Tresiba Flextouch U-100Insulin Degludec85$49,225
Lantus SolostarInsulin Glargine,hum.Rec.Anlog337$42,513
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog86$41,238
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt22$36,627
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog37$33,234
Humalog Kwikpen U-100Insulin Lispro91$32,335
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/721$31,524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog$203$801,726514 claims
Novo NordiskOzempic, Novolog$125$181,123151 claims
Cequr CorporationCequr Simplicity$56$19,47216 claims
Sanofi-aventis U.S. LLCLantus$101$2,45814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Hershey

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →